The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Infection with either influenza A H5N1 virus in 1997 or avian influenza A H7N9 virus in 2013 caused severe pneumonia that did not respond to typical or atypical antimicrobial treatment, and resulted ...

Long before chewing gum came in shiny foil wrappers with watermelon flavors and whitening promises, our ancestors were ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Moderna in May voluntarily withdrew an application seeking approval of its combination shot targeting Covid-19 and influenza, saying it had plans ... flu and respiratory syncytial virus are each multi ...

So far in 2025, 128 cases of dengue fever, a viral disease transmitted through the bite of the Aedes aegypti mosquito, have ...